Search Results

The Cost-Effectiveness of Bosentan in the United Kingdom for Patients with Pulmonary Arterial Hypertension of WHO Functional Class III

Authors: Stevenson, Matt D.; Macdonald, Frances C.; Langley, Jonathan; Hunsche, Elke; Akehurst, Ron

Source: Value in Health, Volume 12, Number 8, November/December 2009 , pp. 1100-1105(6)

Publisher: Blackwell Publishing

Cost-Effectiveness of Using Clinical Risk Factors with and without DXA for Osteoporosis Screening in Postmenopausal Women

Authors: Mueller, Dirk; Gandjour, Afschin

Source: Value in Health, Volume 12, Number 8, November/December 2009 , pp. 1106-1117(12)

Publisher: Blackwell Publishing

The Economic Value of Innovative Treatments over the Product Life Cycle: The Case of Targeted Trastuzumab Therapy for Breast Cancer

Authors: Garrison, Louis P.; Veenstra, David L.

Source: Value in Health, Volume 12, Number 8, November/December 2009 , pp. 1118-1123(6)

Publisher: Blackwell Publishing

International Comparisons in Valuing EQ-5D Health States: A Review and Analysis

Authors: Norman, Richard; Cronin, Paula; Viney, Rosalie; King, Madeleine; Street, Deborah; Ratcliffe, Julie

Source: Value in Health, Volume 12, Number 8, November/December 2009 , pp. 1194-1200(7)

Publisher: Blackwell Publishing

Barriers to Generalizability of Health Economic Evaluations in Latin America and the Caribbean Region

Authors: Augustovski, Federico; Iglesias, Cynthia; Manca, Andrea; Drummond, Michael; Rubinstein, Adolfo; Martí, Sebastián García

Source: PharmacoEconomics, Volume 27, Number 11, 1 November 2009 , pp. 919-929(11)

Publisher: Adis International

Evaluation of Cost-Utility of Varenicline Compared with Existing Smoking Cessation Therapies in South Korea

Authors: Bae, Jung Youn; Kim, Cheol Hwan; Lee, Eui Kyung

Source: Value in Health, Volume 12, Supplement 3, November/December 2009 , pp. S70-S73(1)

Publisher: Blackwell Publishing

A Time-Cost Augmented Economic Evaluation of Oral Deferasirox versus Infusional Dereroxmine for Patients with Iron Overload in South Korea

Authors: Kim, Jinhyun; Kim, Younhee

Source: Value in Health, Volume 12, Supplement 3, November/December 2009 , pp. S78-S81(1)

Publisher: Blackwell Publishing

Cost-Effectiveness Study Comparing Imatinib with Interferon-α for Patients with Newly Diagnosed Chronic-Phase (CP) Chronic Myeloid Leukemia (CML) from the Chinese Public Health-Care System Perspective (CPHSP)

Authors: Chen, Zi; Wang, Chun; Xu, Xiaoping; Feng, Weiwei

Source: Value in Health, Volume 12, Supplement 3, November/December 2009 , pp. S85-S88(1)

Publisher: Blackwell Publishing

Pneumococcal vaccines: search for an optimal agent

Source: PharmacoEconomics and Outcomes News, Volume 1, Number 591, 2009-11-14 , pp. 3-4(2)

Publisher: Adis International

Adjusting for health-related QOL does not appear to substantially affect cost per life year (LY) ratios for most cancer studies

Source: PharmacoEconomics and Outcomes News, Volume 1, Number 591, 2009-11-14 , pp. 6-6(1)

Publisher: Adis International

How does PCV13 stack up against PCV7, -10 and -23?

Source: PharmacoEconomics and Outcomes News, Volume 1, Number 591, 2009-11-14 , pp. 7-7(1)

Publisher: Adis International

The cost utility of pemetrexed as first-line therapy for advanced non-small cell lung cancer appears to be hindered by poor basal QOL

Source: PharmacoEconomics and Outcomes News, Volume 1, Number 591, 2009-11-14 , pp. 8-8(1)

Publisher: Adis International

Postarrest hypothermia produces benefits that justify its costs

Source: PharmacoEconomics and Outcomes News, Volume 1, Number 591, 2009-11-14 , pp. 10-10(1)

Publisher: Adis International

The cost utility of adjuvant trastuzumab therapy for breast cancer appears more favourable in a Canadian population-based cohort

Source: PharmacoEconomics and Outcomes News, Volume 1, Number 591, 2009-11-14 , pp. 11-11(1)

Publisher: Adis International

Insulin glargine dually compared

Source: PharmacoEconomics and Outcomes News, Volume 1, Number 591, 2009-11-14 , pp. 12-12(1)

Publisher: Adis International

Risedronic-acid: more cost effective with wider application

Source: PharmacoEconomics and Outcomes News, Volume 1, Number 591, 2009-11-14 , pp. 12-12(1)

Publisher: Adis International

A nurse-led telephone follow-up accompanied by educational programme appears to be the most cost-effective follow-up strategy

Source: PharmacoEconomics and Outcomes News, Volume 1, Number 591, 2009-11-14 , pp. 13-13(1)

Publisher: Adis International

Insulin aspart looks good for T2DM in Japan

Source: PharmacoEconomics and Outcomes News, Volume 1, Number 589, 2009-10-17 , pp. 4-4(1)

Publisher: Adis International

Never too late to quit. . .

Source: PharmacoEconomics and Outcomes News, Volume 1, Number 589, 2009-10-17 , pp. 4-4(1)

Publisher: Adis International

Natalizumab balanced up in Brazil

Source: PharmacoEconomics and Outcomes News, Volume 1, Number 589, 2009-10-17 , pp. 8-8(1)

Publisher: Adis International